TRHR

Across TCGA pan-cancer cohorts, TRHR Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated TRHR data layer compared with 18 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TRHR Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TRHR expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

HNSC, LUSC, and COAD are the cancer types where TRHR Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	II,III,IV	0.063	0.759	<.001	36	view →
LUSC	OS	Median	III,IV	0.237	0.700	<.001	24	view →
COAD	OS	Median	All	0.111	0.871	<.001	24	view →
BLCA	OS	Median	IV	0.063	0.576	<.001	18	view →
PCPG	DFS	Median	All	0.094	0.768	.008	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	III,IV	0.551	0.242	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

TRHR–HNSC (OS)

Open the HNSC breakdown →